These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26824047)

  • 81. Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "Real World" registry.
    Motovska Z; Ondrakova M; Bednar F; Knot J; Ulman J; Maly M
    Thromb Res; 2015 Jun; 135(6):1093-9. PubMed ID: 25917561
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study.
    Jakubowski JA; Angiolillo DJ; Zhou C; Small DS; Moser BA; Ten Berg JM; Brown PB; James S; Winters KJ; Erlinge D
    Thromb Res; 2014 Sep; 134(3):552-7. PubMed ID: 25022828
    [TBL] [Abstract][Full Text] [Related]  

  • 83. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis.
    Lemesle G; Schurtz G; Bauters C; Hamon M
    J Thromb Haemost; 2015 Jun; 13(6):931-42. PubMed ID: 25809392
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
    Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O
    J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.
    Traby L; Kollars M; Kaider A; Eichinger S; Wolzt M; Kyrle PA
    J Thromb Haemost; 2016 Feb; 14(2):273-81. PubMed ID: 26663880
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Inhibitory Effects of P2Y12 Receptor Antagonist on PAR1- and PAR4-AP-Induced Platelet Aggregation in Patients with Stroke or TIA.
    Kamada A; Shimizu M; Oura K; Yoshida M; Tsuda K; Oi K; Ishigaku Y; Natori T; Narumi S; Itabashi R; Maeda T; Terayama Y
    J Stroke Cerebrovasc Dis; 2021 Mar; 30(3):105547. PubMed ID: 33360254
    [TBL] [Abstract][Full Text] [Related]  

  • 89. In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention.
    Brice AE; Hernandez GA; Sanchez M; Haynick M; Mendoza CE
    Platelets; 2017 May; 28(3):305-309. PubMed ID: 27778525
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis.
    Zhang H; Zhang P; Dong P; Yang X; Wang Y; Zhang H; Yan J; Zhang Y; Zhang T; Li Y
    Coron Artery Dis; 2017 Nov; 28(7):597-604. PubMed ID: 28968313
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.
    Wadowski PP; Eichelberger B; Kopp CW; Pultar J; Seidinger D; Koppensteiner R; Lang IM; Panzer S; Gremmel T
    J Cardiovasc Transl Res; 2017 Aug; 10(4):359-367. PubMed ID: 28425039
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
    Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
    JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.
    Bagoly Z; Sarkady F; Magyar T; Kappelmayer J; Pongrácz E; Csiba L; Muszbek L
    PLoS One; 2013; 8(7):e69417. PubMed ID: 23844259
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
    Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
    Thomas MR; Angiolillo DJ; Bonaca MP; Ajjan RA; Judge HM; Rollini F; Franchi F; Ahsan AJ; Bhatt DL; Kuder JF; Steg PG; Cohen M; Muthusamy R; Sabatine MS; Storey RF
    Thromb Haemost; 2017 May; 117(5):940-947. PubMed ID: 28300867
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A pharmacodynamic study of the optimal P2Y12 inhibitor regimen for East Asian patients with acute coronary syndrome.
    Lee JH; Ahn SG; Park B; Park SW; Kang YS; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J
    Korean J Intern Med; 2015 Sep; 30(5):620-8. PubMed ID: 26354056
    [TBL] [Abstract][Full Text] [Related]  

  • 97. High on-treatment platelet reactivity in patients with ischemic cerebrovascular disease: assessment of prevalence and stability over time using four platelet function tests.
    Jover E; Rodríguez JM; Bernal A; Arroyo AB; Iniesta JA; Guiú IS; Martínez C; Vicente V; Lozano ML; Rivera J
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):604-11. PubMed ID: 24717421
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
    Coleman CI; Limone BL
    Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial.
    Shahzad A; Khanna V; Kemp I; Shaw M; Mars C; Cooper R; Wilson K; Curzen N; Stables RH
    EuroIntervention; 2018 Mar; 13(16):1931-1938. PubMed ID: 29336311
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.
    Wadowski PP; Weikert C; Pultar J; Lee S; Eichelberger B; Koppensteiner R; Lang IM; Panzer S; Gremmel T
    Cardiovasc Drugs Ther; 2020 Feb; 34(1):53-63. PubMed ID: 32062795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.